While these IGF1-R inhibitors have been tested in preclinical breast cancer models [69, 71] and in clinical trials for breast cancer [72], they remain unexplored in clinical trials for IBC, suggesting potential novel therapeutic opportunities, although there are no FDA-approved small-molecule inhibitors of IGF1-R. This evidence concerns the gene IGF1R and breast carcinoma.